To date in the Phase 1/2 portion of the trial, six late-stage participants have been treated with OPGx-LCA5, and all six have experienced clinically meaningful improvements in vision, providing ...
Following completion of the ongoing Phase 2a proof-of-pharmacology study with BMB-101, Bright Minds plans to select and advance a 5-HT 2C molecule (BMB-105) as the dedicated compound for the PWS ...
Achieved record levels of consolidated net revenue, gross profit and Adjusted EBITDANet revenue in Q3 2025 increased by 9% quarter-over-quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback